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The following true story, although pertaining to a rare
condition, is typical of medicine practised in hospitals
and doctors' surgeries every day all over the world. Mrs
M's district nurse phones me - she is with Mr and Mrs
M at their house dressing a leaking exophytic chest wall
lesion. She can see a 'liver like substance' extruding
from a small inferior wound, there is some fresh blood,
and she is concerned that Mrs M may bleed suddenly
and profusely. I ask her to send Mrs M to Casualty.  Mrs
M agrees, but on the condition that she is not admitted
to hospital. Mrs M has mesothelioma and for several
years, has only had a 'few months left to live'. She
presented thirteen years ago with a pleural effusion, for
which no cause was found for seven years. A pleural
biopsy finally showed mesothelioma, and she
underwent chemo and radiotherapy. Unusually for this
type of cancer, Mrs M's months turned into years and
she is now experiencing late manifestations of her
disease, not often seen.  Some months ago she noticed
growth of hard lumps under her right arm, over her
shoulder blade, behind her right breast and above her
right clavicle. Stoical to the utmost, she bought new
clothes and got used to bumping her chin on the lump
above her clavicle every time she turned her head to the
right. She adapted to using her left hand more - for
holding the telephone and stirring soups. Mrs M's
oncologist started her on Thalidomide, an experimental
drug in an oncology setting, with the hope that these
uncomfortable lesions might die away as they are
starved of their blood supply. Within weeks, what were
hard lumps turned to boggy masses. Ultrasound
confirmed a number of large fluid filled spaces, some of
which were amenable to drainage. So, we drained off
two litres of highly viscous blood stained fluid from the
lesion on her back, and two weeks later another litre
from the lesion anteriorly. The lump on which she hit
her chin had also become cystic, so we drained off as
much as we could from there too. I prescribed
antibiotics (whatever the viscous material was, it was
likely to get infected), asked her to check her
temperature at meal times and let us know if she
became febrile, and sent her home for her District
Nurse to review regularly. Six days later I received the
phone call. One of the lumps had become cystic and
had burst through the skin. Her response to the
thalidomide treatment was turning out to be
phenomenal - contrary to all expectations.  
'Mrs M has arrived - let's go down and see her', I say
to my colleague. On the way down, I give him a brief
history, but it is difficult and he clearly has no idea
what to expect. She is in her cubicle with her husband,
perfectly dressed. She transfers to the bed and I undo
the dressing, but before that I get prepared with a pad
and two sick bowls. Nothing fancy.  Immediately, as I
peel back the dressing. the familiar cystic fluid pours
out of the small wound inferiorly. I hold a bowl beneath
it, none spills. My colleague goes pale, and rushes to
put up drips and to attach monitors.  The bowl fills up
and the wound stops draining. I ask Mrs M to sit up,
this time, however, I'm too slow in reaching for an
empty bowl and it pours into her lap, which she handles
with good grace. She does not look and protests good
naturedly when her husband attempts to give a running
commentary. Completely detached, Mrs M appears
remarkably unaffected by this illness, which thirteen
years ago was only going to give her 'a few more
months to live'. We talk about other things - about her
grandchildren coming over the next day for cooked
English breakfast, about the merits of single sex
education, about how she and her husband met, about
the National Heath Service, about all sorts of things.
She tells me how nice it is that since last week she can
turn her head without hitting her chin, and she thanks
me for it, because she knows I missed lunch for it. The
'lump' has drained dry and loose skin hangs where it
had been tense. She has a change of clothes and the
nurses re-dress the wound.  She is ready to go home,
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if her haemoglobin is low. I don't expect it to be, there
was no fresh blood. My colleague is dumbfounded - he
had just watched two litres of what looked like blood
pour out of Mrs M's chest wall and I was sending her
home. The decision to send her home was highly
personalized - I knew her condition and what to expect,
moreover she had a breakfast to cook for her
grandchildren the next day.  
'Personalized medicine' is, however, the term used for
treating patients according to their genes, or, in
oncology, according to their tumour's genes and is far
removed from the type of medicine described in Mrs
M's story. Personalized medicine involves all three
aspects of health care: prevention, detection and
treatment. Personalized medicine uses genetic
information to tailor strategies for these three
cornerstones of health care at the level of the individual.
The rapid advances in genomic sequencing and
bioinformatics are making these dreams come true.
Patients sensitive to drugs such as Azathioprine can
now be identified pre-treatment and their doses adjusted
accordingly - before they experience potentially life-
threatening myelosuppression1. Thousands of cancer
patients are benefiting from targeted drugs such as
Gleevec (for Philadelphia chromosome positive chronic
myeloid leukaemia), Iressa and Tarceva (for certain
patients with non-small cell lung cancer) (2). Many
more such 'designer drugs' are emerging from the
research and development pipelines. Last year, the US
Food and Drug Administration approved the first test to
use genetic information to allow doctors to choose the
most appropriate drugs and doses for their patients. The
AmpliChip test analyses for common variants in two
cytochrome P450 genes (CYP2D6 and CYP2C19)
which play a major role in the metabolism of 25% of all
prescription drugs. The test results place individuals
into one of four categories: 'poor', 'intermediate',
'extensive', or 'ultra rapid' metabolizers. A similar 'p53
chip' is under development for prognostication in
oncology (3).FDA approval of the original AmpliChip
test means approval for this and several other chip-
based testing kits is likely to be rapid.  
These new developments must be seen in the context
of present day life.  Holidays, mobile phone tariffs, pay-
back schemes, you name it, everything these days can
be tailored to your needs.  As in the market place, so in
medicine:  patients will jump at the opportunity to be
treated in a personalized fashion.  As Dr Francis S
Collins, director of the National Human Genome
Research Institute writes:
To realize the full potential of personalized medicine, we
must venture beyond the fields of science and medicine
and into the ethical, legal, and social arenas. For example,
without legislative protections against genetic
discrimination in health insurance and the workplace,
many people will be reluctant to undergo potentially life-
saving genetic tests or to participate in the clinical trials
needed to develop genetically targeted therapies. In
February, the Senate passed the Genetic Information
Nondiscrimination Act of 2005 by a vote of 98-0. The
president has indicated strong support, but the bill remains
before the House of Representatives, with no hearings
scheduled. Given that more than 800 genetic tests are now
available and hundreds more are on the horizon, we need
this legislation.
Other tough questions that we as a society need to ask
ourselves are: Will access to genomic technologies be
equitable? Will knowledge of human genetic variation
reduce prejudice or increase it? What boundaries will need
to be placed on this technology, particularly when applied
to enhancement of traits rather than prevention or
treatment of disease? Will we succumb to genetic
determinism, neglecting the role of the environment and
undervaluing the power of the human spirit?' (4)
Advances in technology will ultimately lead to truly
individualised therapy. However, as clinicians, we must
not lose sight of personalised medicine in every sense
(technology and humanity). It is our role to guide
patients through these advances and translate their test
results into meaningful messages for them. I see clinical
practice in the near future to be an arena where both
personalized and personal medicine co-exist and
complement one another to the benefit of both patients
and society.  
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